TABLE 7

Measures of overall antifungal efficacy and outcome by dosage group

ParameterValue for dosage groupg
2.5 mg/kg (n = 10)5.0 mg/kg (n = 13)7.5 mg/kg (n = 12)10 mg/kg (n = 12)
No. (%) of patients surviving at 4 days posttreatment8 (80)12 (92)10 (83)12 (100)
No. (%) of patients surviving at 2 mo posttreatment8 (80)11 (85)7 (58)11 (92)
No. (%) of patients with breakthrough invasive fungal infection2 (20)a1 (8)b1 (8)c0
No. of patients with baseline invasive fungal infection1d5e1f0
No. of patients with successful treatment of baseline invasive fungal infection1d4e0f0
Type(s) of successful treatment of baseline invasive fungal infectionPartial response2 stabilized, 2 complete responseNoneNA
Type of failure1 relapseProgressionNA
  • a Invasive pulmonary aspergillosis developed in one patient, and Candida parapsilosis fungemia developed in another patient in the study.

  • b Filamentous fungal pneumonia (species not identified).

  • c Invasive pulmonary aspergillosis.

  • d Severe fluconazole-resistant esophageal candidiasis with resolution of odynophagia and dysphagia and partial reduction of mucosal plaques.

  • e One patient had relapsed cryptococcal meningitis after 3 weeks of L-AMB and 4 days of maintenance fluconazole. Among all patients with a successful response, two patients had candidemia caused by C. albicans and C. parapsilosis, which completely resolved, and two patients with invasive pulmonary aspergillosis had stable disease.

  • f One patient died with culture- and biopsy-proven acute pulmonary and hepatic disseminated candidiasis and refractory leukemia after 2 days of L-AMB following withdrawal of all supportive care.

  • g NA, not applicable.